Development of a Nanoparticle-based targeted drug delivery system for cancer therapy

Project Abstract

The development of an advanced nanotechnology-based targeted drug delivery system offers a promising approach to enhance the efficacy and specificity of cancer treatments, thereby reducing systemic toxicity and improving patient outcomes. This research explores the design, synthesis, and characterization of biocompatible nanoparticles engineered to deliver chemotherapeutic agents directly to cancer cells, leveraging ligand-receptor interactions for targeted therapy. The study begins with an extensive review of existing nanoparticle systems, including liposomes, polymeric nanoparticles, and dendrimers, highlighting their strengths and limitations in clinical applications. Subsequently, a novel formulation utilizing biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)) conjugated with targeting ligands like folic acid or antibodies specific to cancer cell markers is developed. The nanoparticles are synthesized via emulsion solvent evaporation techniques, followed by physicochemical characterization using dynamic light scattering (DLS), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR) to determine size, morphology, surface charge, and drug encapsulation efficiency. In vitro studies on cancer cell lines such as MCF-7 and HeLa assess cellular uptake, cytotoxicity, and targeted delivery efficiency, employing assays like MTT, flow cytometry, and confocal microscopy. Results demonstrate that ligand-functionalized nanoparticles significantly enhance selective drug accumulation within tumor cells compared to non-targeted counterparts, resulting in increased cytotoxicity at lower drug doses. Moreover, stability and drug release kinetics are evaluated under physiological conditions, establishing a controlled and sustained release profile that aligns with therapeutic requirements. The study progresses to in vivo assessments using murine models, where biodistribution, tumor suppression efficacy, and systemic toxicity are analyzed through imaging, histopathology, and blood chemistry, confirming superior tumor targeting and minimized adverse effects relative to conventional formulations. Challenges such as nanoparticle aggregation, off-target effects, and immune response are discussed alongside strategies for optimization, including surface modification and dose adjustment. The research concludes by emphasizing the potential of these nanocarriers to revolutionize cancer therapy through personalized, targeted treatment modalities, and proposes further clinical trials to validate safety and efficacy. Overall, this study advances the understanding of nanoparticle-mediated drug delivery, providing a robust platform for developing next-generation chemotherapeutic agents with enhanced precision and reduced side effects, thus contributing significantly to the ongoing efforts in oncological nanomedicine.

Project Overview

What This Project Is About

This project explores how tiny particles called nanoparticles can be used to deliver medicines directly to cancer cells. The goal is to develop a system that can target cancer more accurately, reducing side effects and improving treatment effectiveness. The project involves designing, making, and testing these nanoparticles to see how well they can carry drugs to cancer sites.

The Problem It Addresses

Many cancer treatments spread medicine throughout the body, which can harm healthy cells and cause side effects. Current methods often struggle to deliver enough medicine specifically to the cancer cells. This project aims to create a targeted delivery system that can focus the medicine directly where it’s needed, making treatments safer and more effective for patients.

Objectives of the Project

1. Design and create nanoparticles suitable for drug delivery.
2. Load cancer-fighting drugs onto the nanoparticles.
3. Test the ability of these nanoparticles to target cancer cells in laboratory experiments.
4. Evaluate how well the nanoparticles release the drug at the target site.
5. Assess the safety and toxicity of the nanoparticles in cell tests.

What You Will Do Step by Step

1. Research existing methods for making nanoparticles and choose the best approach.
2. Prepare the nanoparticles in the lab using specified techniques.
3. Attach cancer drugs to the nanoparticles and verify they are correctly loaded.
4. Test the targeting ability by exposing the nanoparticles to cancer cells grown in the lab.
5. Measure how much drug is released over time and verify its effectiveness.
6. Conduct safety tests on healthy cells to check for toxicity.
7. Analyze experimental data to determine how successful the nanoparticles are at targeting cancer cells.
8. Summarize the findings and suggest improvements or future steps.

Expected Outcome

The project is expected to produce a promising nanoparticle system that can accurately target cancer cells and efficiently deliver the medicine. This could lead to safer cancer treatments with fewer side effects and help advance research in targeted drug delivery technologies.